Page last updated: 2024-10-22

amifostine anhydrous and Candidiasis, Oral

amifostine anhydrous has been researched along with Candidiasis, Oral in 1 studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Candidiasis, Oral: Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"Oral candidiasis is suggested as an objective, early, though indirect, endpoint for amifostine's radioprotective effect on salivary glands."2.71Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. ( Dardoufas, K; Kolitsi, G; Kouloulias, V; Kyprianou, K; Nicolatou-Galitis, O; Papanikolaou, I; Pissakas, G; Sotiropoulou-Lontou, A; Velegraki, A; Yiotakis, I, 2003)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nicolatou-Galitis, O1
Sotiropoulou-Lontou, A1
Velegraki, A1
Pissakas, G1
Kolitsi, G1
Kyprianou, K1
Kouloulias, V1
Papanikolaou, I1
Yiotakis, I1
Dardoufas, K1

Trials

1 trial available for amifostine anhydrous and Candidiasis, Oral

ArticleYear
Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Oral oncology, 2003, Volume: 39, Issue:4

    Topics: Amifostine; Candidiasis, Oral; Female; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Middle

2003